If you are researching weight loss medications right now, the retatrutide vs tirzepatide comparison is the one that matters most. Both drugs come from Eli Lilly, both are once-weekly injections, and both target overlapping gut-hormone receptors. But they are not the same compound, and they are not at the same stage of availability. Tirzepatide is FDA-approved and on pharmacy shelves today as Zepbound and Mounjaro. Retatrutide is an investigational triple agonist that has delivered the highest average weight loss ever seen in a Phase 3 obesity trial — 28.7% at 68 weeks. Understanding the difference between these two peptides means understanding whether the extra weight loss justifies the longer wait and the higher side-effect burden.
Mechanism: Triple Agonist vs Dual Agonist
The most important difference between retatrutide and tirzepatide is how many hormone receptors each drug activates. Tirzepatide is a dual agonist — it targets the GIP receptor and the GLP-1 receptor. Retatrutide is a triple agonist — it targets those same two receptors plus the glucagon receptor. That single additional receptor changes everything. Source: Rosenstock et al., “Efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in type 2 diabetes,” The Lancet, 2023.
GLP-1 receptor activation reduces appetite, slows gastric emptying, and stimulates insulin secretion in response to food. GIP agonism amplifies those effects, improves insulin sensitivity, and influences how fat cells store and release energy. Together, these two mechanisms produce powerful appetite suppression — which is why tirzepatide outperforms semaglutide. But neither receptor directly increases how many calories the body burns. Source: Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” New England Journal of Medicine, 2022.
Retatrutide adds glucagon receptor agonism to that same dual backbone. Glucagon activates thermogenesis in brown adipose tissue — your body burns more energy as heat. It also drives the liver to oxidize stored fat more aggressively. The net effect is that retatrutide attacks obesity from both directions: reduced calorie intake from GLP-1 and GIP, and increased energy expenditure from glucagon. The result is a weight-loss profile that approaches what bariatric surgery delivers. Source: Heise et al., “Triple GIP, GLP-1, and Glucagon Receptor Agonism in Obesity,” The Lancet, 2024.
Weight Loss Results: 28.7% vs 22.5%
The weight loss data comes from two separate Phase 3 trial programs: SURMOUNT for tirzepatide and TRIUMPH for retatrutide. These trials enrolled different patient groups at different times, but the efficacy gap is consistent across every published analysis.
Tirzepatide’s SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight and at least one weight-related comorbidity, excluding type 2 diabetes. After 72 weeks, participants taking the 15 mg dose achieved an average weight loss of 22.5% from baseline. The 10 mg dose produced 21.4%, and the 5 mg dose produced 15.0%. More than half of participants on the highest dose lost at least 20% of their body weight. Source: Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” NEJM, 2022.
Retatrutide’s TRIUMPH-4 trial published in December 2025 evaluated 445 adults with obesity and knee osteoarthritis. The 12 mg dose delivered an average weight loss of 28.7% at 68 weeks — roughly 71.2 pounds from a baseline of about 248.5 pounds. The 9 mg dose produced 26.4%. Nearly 60% of participants on 12 mg lost at least 25% of their body weight, and 39.4% lost at least 30%. Retatrutide is the first obesity medication where a majority of participants achieved 25% or greater weight loss in a Phase 3 trial — a threshold previously accessible only through bariatric surgery. Source: Eli Lilly, “TRIUMPH-4 Topline Results,” Press Release, December 11, 2025.
Earlier data from TRIUMPH-1, which completed in May 2026, showed consistent results: 28.3% average weight loss at 80 weeks and 30.3% in the high-BMI subgroup at 104 weeks. The Phase 2 data published in 2023 had already signaled this trajectory, with 24.2% weight loss at 48 weeks on the 12 mg dose and no plateau at study end. Source: Rosenstock et al., “Retatrutide Phase 2 Results,” The Lancet, 2023.
In practical terms, a person starting at 250 pounds would lose roughly 56 pounds on tirzepatide 15 mg and roughly 72 pounds on retatrutide 12 mg — a difference of about 16 pounds. A 2025 network meta-analysis published in the Journal of the Endocrine Society confirmed this across trials, finding retatrutide produced -16.34 kg absolute weight reduction versus tirzepatide’s -11.82 kg.
Side Effects and Tolerability: The Trade-Off
Higher efficacy comes with a higher side-effect burden. This is the central trade-off in the retatrutide vs tirzepatide comparison, and it is not close.
Tirzepatide side effects (SURMOUNT-1, 15 mg dose):
- Nausea: 33%
- Diarrhea: 21%
- Vomiting: 10%
- Discontinuation due to adverse events: 10.5%
Retatrutide side effects (TRIUMPH-4, 12 mg dose):
- Nausea: 43%
- Diarrhea: 33%
- Vomiting: 21%
- Discontinuation due to adverse events: 18.2%
The gastrointestinal side effects are higher across the board for retatrutide — roughly double the vomiting rate and nearly double the drug-discontinuation rate compared to tirzepatide. Most GI events are described as mild to moderate and occur during the dose-escalation phase, but the difference is real. Source: Jastreboff (SURMOUNT-1, NEJM 2022) and Eli Lilly TRIUMPH-4 press release, 2025.
Retatrutide also has a side effect that tirzepatide does not: dysesthesia. In TRIUMPH-4, 20.9% of participants on the 12 mg dose reported tingling, burning, or prickling skin sensations. This was typically described as mild and rarely led to discontinuation, but it is unique to the glucagon receptor component and has not been observed with dual agonists alone.
On the positive side, retatrutide produced larger cardiovascular risk-marker improvements than tirzepatide. Systolic blood pressure dropped 14.0 mmHg with retatrutide 12 mg versus 7.4 mmHg with tirzepatide 15 mg. Retatrutide also reduced non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP). Neither drug has completed a dedicated cardiovascular outcomes trial at this point — tirzepatide’s SURMOUNT-MMO and retatrutide’s cardiovascular study are both ongoing with results expected in 2027-2028. Source: Eli Lilly TRIUMPH-4 data presentation, 2025.
Dosing, Titration, and Administration
Both drugs are administered as once-weekly subcutaneous injections. Both use gradual dose escalation to improve tolerability. But the dosing schedules are not identical.
Tirzepatide starts at 2.5 mg weekly for four weeks, then increases to 5 mg. From there, titration proceeds in 2.5 mg increments every four weeks up to the maximum dose of 15 mg weekly. A typical patient reaches the therapeutic range at 5-10 mg and can stay at that level if adequate weight loss is achieved. Source: Eli Lilly, Zepbound Prescribing Information, 2023.
Retatrutide’s titration schedule from the TRIUMPH trials starts at 2 mg weekly, escalating to 4 mg, then 6 mg, then 9 mg, with the option to go to 12 mg. Each dose level is maintained for four weeks. The Phase 3 program uses a maximum of 12 mg weekly. Unlike tirzepatide, retatrutide’s final dose is still under investigation — the ongoing TRIUMPH-5 head-to-head trial against tirzepatide will help determine whether the highest dose is appropriate for all patients or reserved for those who need maximum efficacy. Source: Eli Lilly, TRIUMPH-4 protocol, ClinicalTrials.gov NCT05929066.
The half-life difference is small but relevant. Tirzepatide has an approximately 5-day plasma half-life, and retatrutide approximately 6 days. Both support once-weekly dosing with stable drug exposure throughout the week. Steady state is reached in approximately four weeks for both drugs.
FDA Status, Availability, and Cost
This is where the comparison becomes a practical decision rather than a theoretical one.
Tirzepatide is FDA-approved for two indications: Zepbound for chronic weight management (approved November 2023) and Mounjaro for type 2 diabetes (approved May 2022). Both are widely available at retail pharmacies with a prescription. The list price for Zepbound is approximately $1,060 per month before insurance, though many patients pay less through manufacturer savings programs or insurance coverage. Compounded tirzepatide is available from licensed pharmacies at significantly lower prices, typically ranging from $125-$400 per month depending on dose. Source: Lilly.com/pricing.
Retatrutide has no fda approval, no EMA approval, and no regulatory approval anywhere in the world. It is exclusively available through Eli Lilly’s ongoing Phase 3 TRIUMPH clinical trials. The earliest possible FDA approval is estimated at 2027-2028, based on the current TRIUMPH program timeline. Seven additional Phase 3 trials in obesity and type 2 diabetes are expected to complete in 2026, which will form the basis of the New Drug Application submission. Source: ClinicalTrials.gov search for TRIUMPH retatrutide trials; Eli Lilly investor communications, 2025.
Cost projections for retatrutide once approved are speculative at this stage. Based on Eli Lilly’s pricing strategy for tirzepatide and the premium that higher-efficacy drugs typically command, analysts estimate a list price in the range of $1,200-$1,500 per month. Whether insurance covers it will depend on FDA approval specifics, formulary decisions, and the competitive landscape at the time of launch.
Which One Should You Choose?
The answer depends entirely on your timeline and your weight-loss goals. If you need to start treatment now, the decision is made for you: tirzepatide is available today with proven 22.5% average weight loss, well-characterized side effects, and established real-world data across hundreds of thousands of patients. It is the most powerful approved weight loss medication on the market as of 2026. Source: Zepbound prescribing information; SURMOUNT-1 trial data.
If you are willing to wait, retatrutide offers roughly six additional percentage points of weight loss — enough to push someone from the obese category into a healthy weight range who would not get there with tirzepatide alone. But waiting means delaying treatment for 12-24 months minimum, and retatrutide’s side-effect burden is meaningfully higher. That extra 6% of weight loss comes with roughly double the vomiting rate and dysesthesia in one-fifth of patients.
The TRIUMPH-5 head-to-head trial, which is actively enrolling approximately 800 participants to compare retatrutide directly against tirzepatide, will provide the definitive answer when results are published around April 2027. Until then, each patient must weigh available evidence against personal health circumstances and timeline.
A reasonable approach: start tirzepatide now if your BMI qualifies and your doctor prescribes it. The weight loss you achieve in the next 12 months — and the health improvements that come with it — are not hypothetical. If retatrutide is approved and you want to switch at that point, the option will exist. Waiting for a potentially better drug that does not yet exist carries its own health cost: the weight you could have lost in the meantime.
Leave a Reply